Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures April 28, 2023 AutoBot News 0 clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.